Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 1542
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Katz, A. Articles by Gansl, R. C. Search for Related Content PubMed Articles by Katz, A. Articles by Gansl, R. C.

Abstract

Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy

CPO - Albert Einstein Hospital, Sao Paulo, Brazil; PUC-RS School of Medicine, Porto Alegre, Brazil

1542

Background: High-grade gliomas (HGG) PTS progressing after surgery, radiation therapy and chemotherapy with Temozolomide have a very short survival. No particular form of therapy has been shown to be effective in this setting. It is also known that the genetic pathways leading to primary and secondary gliomas are markedly different. A significant proportion of younger PTS who develop secondary glioblastomas (GBM) have amplification of the PDGFR alfa, while PTS with de novo GBMs usually do not have this alteration. Molecular targeted therapy need to take these disease characteristics into account in order to be adequately evaluated. Imatinib (Gleevec) have been shown to be active in preclinical models against glioblastoma cell lines and in xenograft models. Methods: We treated 15 PTS with HGG who developed progressive disease after being treated with surgery, radiation therapy and temozolomide. 14/15 PTS were PDGR alfa positive by Immunohistochemistry. All PTS were treated with Imatinib 400 mg/day until progression of disease. Median age was 62, 9/15 PTS were older then 45 years old. Results: Among these older PTS only 1 remained in stable disease for 8+ months, while the others developed progression of disease. Three of the six PTS younger than 45 y.o. responded to the treatment (one to early): 1PR (14+ months), 1 SD (8 months), 1 MR (19 months). Treatment was well tolerated in general and no grade toxicities were observed. Conclusion: Imatinib seems to be active in a proportion of PTS with progressive HGG. Although these are very small numbers, we speculate that these results may suggest that this drug could be especially active in PTS with secondary HGG, in whom the PDGFR alfa may play an important role in the gliomagenesis process. The trial is still open for accrual and prospective evaluation of gene expression and tissue array were recently incorporated into the study.

No significant financial relationships to disclose.

Abstract presentation from the 2004 ASCO Annual Meeting